Recruiting
Study of Lutetium-177-DOTA-TATE with octreotide LAR in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) with high disease burden
Registered drugNo placebo
Study of Lutetium-177-DOTA-TATE with octreotide LAR in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) with high disease burden
Registered drugNo placebo
- Disease:Gastroenteropancreatic neuroendocrine tumour disease
- Substances:DimeticoneLysine Hydrochloride+7
Countries:
France
France- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Dimeticone



